Treosulfan Dosage

Medically reviewed by Drugs.com. Last updated on Mar 24, 2025.

Usual Adult Dose for Stem Cell Transplant Conditioning

Treosulfan: 10 g/m2 IV once a day for 3 days (day -4, -3, -2) before stem cell infusion (day 0)

Fludarabine: 30 mg/m2 IV infusion once a day, for 5 days (day -6, -5, -4, -3, -2) before stem cell infusion (day 0)

Comments:

• This drug is administered as a 2-hour IV infusion.
• This drug should be administered before fludarabine on days -4, -3, -2.
• Premedicate the patients with antiemetics before administering this drug.
• This drug is used in combination with fludarabine. Consult the manufacturer product information of fludarabine for more information.
• Monitor for extravasation, if extravasation occurs, stop the infusion.

Use: In combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia and myelodysplastic syndrome

Usual Pediatric Dose for Stem Cell Transplant Conditioning

1 Year and Older:
Treosulfan: 10 g/m2 IV once a day for 3 days (day -4, -3, -2) before stem cell infusion (day 0)

Fludarabine: 30 mg/m2 IV infusion once a day, for 5 days (day -6, -5, -4, -3, -2) before stem cell infusion (day 0)

Comments:

• This drug is administered as a 2-hour IV infusion.
• This drug should be administered before fludarabine on days -4, -3, -2.
• Premedicate the patients with antiemetics before administering this drug.
• This drug is used in combination with fludarabine. Consult the manufacturer product information of fludarabine for more information.
• Monitor for extravasation, if extravasation occurs, stop the infusion.

Use: In combination with fludarabine as a preparative regimen for allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:
Myelosuppression: This drug causes severe and prolonged myelosuppression at the recommended dosage. HSCT is required to prevent potentially fatal complications of prolonged myelosuppression. Monitor hematologic laboratory parameters.

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Inspect the reconstituted solution for discoloration and particulate matter.
• Do not use if the reconstituted solution contains a precipitate.
• If reconstituted solution is not used immediately, it can be stored at room temperature 20C to 25C (68F to 77F) for up to 24 hours. Do not refrigerate.
• Confirm patency of the intravenous line prior to infusion.
• Consult the manufacturer product information of fludarabine for more information.

Storage requirements:

• Store single dose vials at 20C to 25C (68F to 77F) with excursions permitted between 15C and 30C.
• Reconstituted solution is stable for 1 day at room temperature 20C to 25C (68F to 77F). Do not refrigerate.

Reconstitution/preparation techniques:

• This drug should be reconstituted with any one of the following before IV infusion: 0.45% sodium chloride injection, 0.9% sodium chloride injection, 5% dextrose injection, or sterile water for injection.
• The manufacturer product information should be consulted.

IV compatibility:

• 0.45% Sodium Chloride Injection
• 0.9% Sodium Chloride Injection
• 5% Dextrose Injection
• Sterile Water for Injection

Monitoring:

• General: Extravasation, intravenous infusion site for redness, swelling, pain, infection, and necrosis (during and after the dose)
• Hematologic: Blood cell counts (once a day until hematopoietic recovery), hematologic laboratory parameters
• Nervous system: Neurological adverse reactions

Patient advice:

• Read the US FDA-approved patient labeling.
• Patients should be advised to report any signs or symptoms of an infection.
• Clean sweaty skin parts (armpit, groin, genital area, inframammary line), each with a disposable washcloth and clear water.
• Do not apply any cream to the skin on the days of chemotherapy, and clothing should not be too tight, in order to let the skin, breathe.
• Females should be advised not to breastfeed during therapy with this drug and for 1 week after the last dose.
• Females of childbearing potential should be advised to use effective birth control during treatment and for 6 months after the last dose.
• Males with female partners of reproductive potential should use effective contraception during treatment with this drug and for 3 months after the last dose.
• This drug can impair fertility in females and males and may cause temporary or permanent infertility.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer